If your facility has ever faced a delayed product launch, a failed regulatory inspection, or a costly batch rejection, there is a good chance the root cause traced back to gaps in CQV. With this practical guide, you can build a CQV program that holds up when it matters most.
CQV stands for Commissioning, Qualification, and Validation. It’s the structured, lifecycle-based program that ensures your facilities, equipment, and manufacturing processes consistently perform as intended, every single time.
At its core, CQV is the documented evidence that your manufacturing operation is fit for purpose. Regulatory bodies, including the FDA (21 CFR Part 211), EU GMP Annex 15, and ICH guidelines Q7 and Q10, require manufacturers to demonstrate documented, repeatable control over their systems and processes.
But compliance is the floor, not the ceiling. When challenges arise, it’s often because CQV was treated as a checklist rather than a lifecycle commitment. The manufacturers who get the most out of CQV are the ones who treat it as a strategic program, not a regulatory obligation to be fulfilled and forgotten.
Understanding where programs break down is the first step toward building one that doesn’t.
Commissioning: The Engineering Foundation You Cannot Afford to Skip
Commissioning is the first phase of CQV, and it is often the most underestimated. This is the engineering-driven process of verifying that systems and equipment have been installed correctly, are operating as designed, and are ready to hand over to the qualification team.
Key commissioning activities include Factory Acceptance Testing (FAT), Site Acceptance Testing (SAT), outstanding items sign-off, and formal system turnover documentation.
Here is the critical distinction you need to understand: commissioning is not a GMP activity. It sits outside the formal regulatory framework. But that does not make it optional. A rigorous commissioning phase directly reduces the scope and duration of qualification, which means less rework and faster timelines to operation.
Where programs most often go wrong here is simple: commissioning gets compressed to protect the schedule. But the cost shows up in qualification, in the form of deviations, failed tests, and rework that takes longer to resolve than the time that was saved.
Qualification: The Regulatory Heart of Your CQV Program
If commissioning builds the platform, qualification is where your regulatory obligations begin in earnest. This is the GMP-regulated phase that provides formal, documented evidence that your equipment and systems perform as intended under defined conditions.
Qualification is typically broken into four stages:
- Design Qualification (DQ): Does the design of the equipment or system meet your user requirements and applicable regulatory standards? DQ is where you confirm on paper, before anything is built or installed, that the solution is fit for its intended purpose.
- Installation Qualification (IQ): Was the system installed correctly and in accordance with approved specifications? IQ creates the documented record that everything is where it should be and connected as designed.
- Operational Qualification (OQ): Does the system operate within its defined parameters? OQ tests the equipment through its operational ranges, confirming it performs as specified under controlled conditions.
- Performance Qualification (PQ): Does the system consistently perform under actual production conditions? PQ is the final proof that the equipment is ready for real-world use.
Regulators today encourage a risk-based approach to qualification. High-risk product-contact systems (such as mixing vessels or filling equipment that directly contact your product) require rigorous qualification; lower-risk utility systems may require less. A smart CQV strategy allocates effort where it matters most.
The most common failure mode in qualification is treating it as a documentation exercise. Teams focus on producing the paperwork rather than genuinely stress-testing systems against their intended use. That approach may clear an internal milestone, but it rarely holds up under close regulatory scrutiny. Qualification is the phase most scrutinized during FDA and EU GMP inspections, and gaps in this phase are among the most common sources of FDA Form 483 observations and warning letters (formal notices of regulatory deficiencies).
Validation: Proving Your Process Delivers at Scale
Validation is where CQV connects directly to your product and your patients. While qualification focuses on equipment and systems, validation focuses on the manufacturing process itself, providing documented evidence that it reliably and reproducibly produces a product meeting its predetermined specifications.
The FDA’s guidance on process validation outlines a three-stage lifecycle model:
- Stage 1 – Process Design: Defining how the commercial manufacturing process will work, based on knowledge built during development.
- Stage 2 – Process Qualification: Confirming that the process can be reproduced consistently at commercial scale.
- Stage 3 – Continued Process Verification: Monitoring the process during routine production to confirm it continues to perform as expected.
Beyond process validation, executives should be aware of several other validation types that typically fall under a CQV program: cleaning validation (proving equipment is adequately cleaned between products or batches), computer system validation (CSV), and analytical method validation.
Where validation programs most commonly fall short is Stage 3. Process Design and Process Qualification get the attention because they are tied to launch milestones. Continued Process Verification gets deprioritized once commercial production begins. The result is a process that was validated at one point in time but has since drifted, been modified, or scaled in ways that were never formally captured. That is a significant exposure, and one that regulators are increasingly focused on.
Why CQV in Pharmaceutical Manufacturing Must Work as One Unified Program
One of the most costly mistakes you can make is treating commissioning, qualification, and validation as three separate, siloed workstreams. The truth is, they are sequential and deeply interdependent.
Commissioning creates the platform. Qualification confirms the building blocks. And validation proves that the entire system delivers on its promises. Poor handoffs between phases or gaps in change control at any stage can unravel the integrity of the whole program.
The most effective CQV programs are built on a unified strategy from day one, with a risk-based approach that scales effort to consequence.
READ MORE: Best Practices for Implementing CQV in Oral Solid Dosage Manufacturing: A Client-Centered Approach
Four CQV Pitfalls Every Pharma Leader Should Recognize
Even well-resourced organizations make avoidable mistakes. These are the four that show up most often and have the highest downstream cost.
- Treating CQV as a one-time event. Validation does not end at commercial launch. Processes change, equipment ages, and regulatory expectations evolve. Organizations that close out their CQV program at go-live and move on are often the ones caught flat-footed during re-inspections or when a process change triggers a revalidation requirement they did not anticipate.
- Underinvesting in commissioning. As noted above, this is the most predictable way to create qualification problems. The cost is not always immediately visible, but it accumulates as delays, deviations, and rework that could have been avoided with more rigorous upfront work.
- Weak change control after initial validation. Processes get modified. Equipment gets upgraded. Formulations get adjusted. Every one of those changes carries the potential to invalidate prior validation work if change control is not managed carefully. This is one of the most common findings during re-inspections of facilities that previously passed without issue.
- Siloed teams with poor documentation handoffs. CQV spans engineering, quality, operations, and often external contractors. When those teams do not communicate well, or documentation does not transfer cleanly between phases, gaps form. Those gaps rarely surface until an inspector finds them.
READ MORE: Ensuring Compliance and Product Quality in Formulation and Filling: A CQV Perspective
Knowing CQV Is Not the Same as Executing It Well
The gap between understanding CQV and running a program that holds up under real-world conditions is where most of the risk lives. The leaders who navigate that gap most effectively are the ones who treat CQV as an ongoing operational discipline, invest appropriately across all three phases, and build teams and processes that can sustain the program well beyond initial launch.
Whether you are planning a new facility build, scaling an existing process, or preparing for an upcoming inspection, the strength of your CQV program will determine your readiness.
CQV done right is not just about passing inspections. It is about building a manufacturing program you can stand behind. If you are looking for a partner who has worked on programs like yours, we would love to talk. Reach out to our team today.
